NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of “Hold” from Brokerages

NeoGenomics, Inc. (NASDAQ:NEO) has received an average recommendation of “Hold” from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $12.5556.

NEO has been the topic of several research reports. TD Cowen raised their price objective on shares of NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Cowen restated a “buy” rating on shares of NeoGenomics in a research report on Friday, September 12th. Stephens raised their price objective on shares of NeoGenomics from $6.50 to $11.00 and gave the company an “overweight” rating in a research report on Tuesday, September 2nd. William Blair restated a “market perform” rating on shares of NeoGenomics in a research report on Tuesday, July 29th. Finally, Piper Sandler set a $11.00 price objective on shares of NeoGenomics and gave the company an “overweight” rating in a research report on Monday, August 4th.

Hedge Funds Weigh In On NeoGenomics

Institutional investors and hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group bought a new position in shares of NeoGenomics during the 1st quarter valued at $35,000. Headlands Technologies LLC bought a new position in shares of NeoGenomics during the 2nd quarter valued at $32,000. CWM LLC grew its holdings in shares of NeoGenomics by 42.6% during the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 1,883 shares during the last quarter. AlphaQuest LLC bought a new position in shares of NeoGenomics during the 1st quarter valued at $60,000. Finally, Moors & Cabot Inc. bought a new position in shares of NeoGenomics during the 1st quarter valued at $95,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

NASDAQ NEO opened at $7.86 on Friday. The company’s 50 day simple moving average is $6.93 and its two-hundred day simple moving average is $7.80. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.92 and a quick ratio of 3.58. The stock has a market capitalization of $1.02 billion, a PE ratio of -9.70 and a beta of 1.62. NeoGenomics has a 1 year low of $4.72 and a 1 year high of $19.11.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.